These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29872916)

  • 1. Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.
    Moilanen T; Jokimäki A; Tenhunen O; Koivunen JP
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1613-1621. PubMed ID: 29872916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman.
    Alghafar DA; Younos I; Baimani KA; Al-Salhi D; Al-Riyami A; Rizvi S; Buckley NE
    J Oncol Pharm Pract; 2021 Mar; 27(2):312-321. PubMed ID: 32340535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
    Lidbrink E; Chmielowska E; Otremba B; Bouhlel A; Lauer S; Liste Hermoso M; Nüesch E; Shing M; Misra V
    Breast Cancer Res Treat; 2019 Feb; 174(1):187-196. PubMed ID: 30506110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
    Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
    Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.
    Kosalka P; Johnson C; Turek M; Sulpher J; Law A; Botros J; Dent S; Aseyev O
    Curr Oncol; 2019 Jun; 26(3):e314-e321. PubMed ID: 31285674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer.
    Grazziotin LR; Picon PD
    J Oncol Pharm Pract; 2017 Jun; 23(4):264-272. PubMed ID: 26983449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
    JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
    Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
    Abouegylah M; Braunstein LZ; Alm El-Din MA; Niemierko A; Salama L; Elebrashi M; Edgington SK; Remillard K; Napolitano B; Naoum GE; Sayegh HE; Gillespie T; Farouk M; Ismail AA; Taghian AG
    Breast Cancer Res Treat; 2019 Feb; 174(1):179-185. PubMed ID: 30478787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?
    Barron CC; Tyagi NK; Alhussein MM; Mukherjee SD; Ellis PM; Dhesy-Thind S; Leong DP
    Oncologist; 2019 Nov; 24(11):1405-1409. PubMed ID: 31315962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
    Stanton SE; Ward MM; Christos P; Sanford R; Lam C; Cobham MV; Donovan D; Scheff RJ; Cigler T; Moore A; Vahdat LT; Lane ME; Chuang E
    BMC Cancer; 2015 Apr; 15():267. PubMed ID: 25885598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.
    Vazdar L; Gabrić ID; Kruljac I; Pintarić H; Šeparović R; Kirigin Biloš LS; Pavlović M; Tečić Vuger A; Štefanović M
    Sci Rep; 2021 Jul; 11(1):14395. PubMed ID: 34257352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients.
    Toukabri I; Ben Said A; Hamdi A; Aloulou A; Ben Ayed W; Cherif I; Limayem I
    J Oncol Pharm Pract; 2023 Apr; 29(3):613-618. PubMed ID: 35088630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.